CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹7,014 Cr | ₹5,484 Cr | ₹5,246 Cr | ₹5,033 Cr | ₹4,913 Cr |
What is the latest Total Current Liabilities ratio of CIPLA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹7,014 Cr |
| Mar2025 | ₹5,484 Cr |
| Mar2024 | ₹5,246 Cr |
| Mar2023 | ₹5,033 Cr |
| Mar2022 | ₹4,913 Cr |
How is Total Current Liabilities of CIPLA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹7,014 Cr | 27.89 | |
| Mar2025 | ₹5,484 Cr | 4.54 | |
| Mar2024 | ₹5,246 Cr | 4.22 | |
| Mar2023 | ₹5,033 Cr | 2.45 | |
| Mar2022 | ₹4,913 Cr | - | |
Compare Total Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹113,887.7 Cr | -1.6% | -2.1% | -4.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹473,509.0 Cr | 0.6% | 6% | 14.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹196,881.0 Cr | 1.2% | 10.5% | 7.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,832.0 Cr | -0.4% | 11% | 40.8% | Stock Analytics | |
| MANKIND PHARMA | ₹105,357.0 Cr | -1% | 3.7% | -5.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,062.8 Cr | -4.6% | -14.8% | -8.4% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -1.6% |
-2.1% |
-4.8% |
| SENSEX | -1.1% |
-0.2% |
-6.6% |
You may also like the below Video Courses